Antiandrogen withdrawal response is an increasingly recognized entity in patients with metastatic prostate cancer. To our knowledge, there have been no reports describing a durable radiologic improvement along with prostate-specific antigen (PSA) with discontinuation of the antiandrogen agent bicalutamide. We report a case in which a dramatic decline of serum PSA levels associated with a dramatic improvement in radiologic disease was achieved with bicalutamide discontinuation.
|Original language||English (US)|
|Journal||Journal of Hematology and Oncology|
|State||Published - 2008|
All Science Journal Classification (ASJC) codes
- Molecular Biology
- Cancer Research